Stage IIIA non-small-cell lung cancer occurs in a heterogenous group of patients for whom the best treatment is multimodality therapy with chemotherapy, radiation, and surgery in a select group of individuals. This clinical review intends to answer the most common questions that clinicians face in the decision about the best management in this group.
INTRODUCTION
The past decade has seen major advances in the therapy of non-small-cell lung cancer (NSCLC ; Table 1 ). Yet, for patients with stage III disease, such advances have been limited. Despite the fact that therapy of stage III has changed little during the past decade, a number of open questions remain about its management. The purpose of this concise review is to address some of these.
WHAT ARE THE APPROPRIATE STAGING STUDIES FOR PATIENTS DIAGNOSED WITH STAGE III DISEASE?
Stage III NSCLC is defined as locoregionally advanced disease because of either the extension of the primary tumor (eg, a T3 lesion with hilar lymph nodes or a T4 lesion) or the involvement of mediastinal lymph nodes (N2 or N3) without evidence of distant metastatic disease. The American College of Chest Physicians has proposed the following recommendations 1 : For all patients with suspected or confirmed lung cancer, a contrast-enhanced chest and upper abdomen computed tomography (CT) scan is recommended as an initial step. In the absence of distant metastasis and when the patient is eligible for curative treatment, a positron emission tomography (PET) scan is recommended. If this study shows overwhelming radiographic evidence of metastatic disease in multiple sites, there is no need to conduct histologic confirmation of the metastatic lesions; however, if the evidence is not overwhelming or if there is a clinical suspicion of a different disease process, tissue sampling to pathologically confirm stage IV disease is recommended. For mediastinal staging, if a patient has extensive mediastinal infiltration (discrete lymph nodes can no longer be discerned or measured), pathologic assessment of the mediastinum is not necessary. In contrast, if there is discrete mediastinal lymph node enlargement, even in the presence of fluorodeoxyglucose avidity-because the PET scan diagnostic capabilities range from 0.77 to 0.81 for sensitivity and 0.79 to 0.90 for specificity 2 -histologic confirmation of mediastinal involvement is warranted. Similarly, in patients who present with a central tumor or a tumor with enlarged N1 nodes and who have a normal mediastinum by imaging, histologic confirmation of involvement of mediastinal nodes is required, because the presence of occult mediastinal nodal involvement can be as high as 25%, despite normal imaging studies. 1 When histologic confirmation is required, this can be done through either needle-based techniques (eg, endoscopic bronchial ultrasound or esophageal ultrasound) or by a videoassisted mediastinoscopy, dependent upon the resources and expertise available at each center. Currently, for patients who have enlarged mediastinal lymph nodes on CT scans or high uptake on PET scans, a negative endoscopic bronchial ultrasound or esophageal ultrasound should be followed by a surgical biopsy. 3 Up to 16% of patients with apparent stage III lung cancers have brain metastases at diagnosis, which greatly influences prognosis. 4 whether surgery was beneficial in the treatment of patients with ipsilateral mediastinal involvement after neoadjuvant therapy. In the European study, neoadjuvant platinum-based chemotherapy was delivered to all patients, and those with some response were randomly assigned to receive localized therapy with surgery or radiotherapy. There was no difference in overall survival (OS) between the two groups. This study has been criticized, because only 50% of the patients randomly assigned to surgery had a complete microscopic tumor resection (R0) and because 47% of the surgical procedures, a rate considered high, were pneumonectomies. In the North American trial, patients were treated with a combination of cisplatin-based chemoradiotherapy to a dose of 45 Gy followed by random assignment to surgery or the completion of radiotherapy to 61 Gy. After the conclusion of local therapy, patients were to receive two additional cycles of chemotherapy. In contrast to the European study, pneumonectomies were performed in 35% of patients randomly assigned to surgery, and 71% had an R0 resection. Again, there was no difference in OS (23.6 v 22.2 months; hazard ratio [HR], 0.87; 95% CI, 0.70 to 1.10; P 5 .24). Patients in the surgical arm had better progressionfree survival (PFS); in an exploratory analysis, those treated with a lobectomy had better OS with surgery. Conversely, patients treated with a pneumonectomy had a worse outcome with surgery and had a high perioperative mortality of 26%. 8 Despite the negative results of these studies, it is clear that a subset of patients benefits from surgery. However, in part because of the heterogeneity of the disease, identification of such patients has been extremely challenging. 10 Our institutional approach is to offer surgery for patients who have stage IIIA disease if only one mediastinal lymph node station is involved and if that node is smaller than 3 cm. This recommendation is shared among others cancer centers; in fact, a survey done among institution members of the NCCN showed that 90% of the responders would consider surgery as part of the therapy in this same clinical scenario.
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When surgery is considered, it is paramount to involve the surgery team in the initial evaluation. This initial assessment should confirm the presence of N2 disease and rule out N3 involvement, which would stage the disease as IIIB and therefore exclude surgery from treatment. Furthermore, surgery should be doneinhigh-volumecenters 12 and by surgeons who have most of their practice dedicated to lung cancer, 13 because these factors have been associated with improved survival.
WHAT IS THE BEST CHEMOTHERAPY REGIMEN CONCURRENT TO RADIATION?
Randomized controlled trials have demonstrated that concurrent chemoradiotherapy improves OS but increases toxicity compared with sequential chemoradiotherapy. 14, 15 Several chemotherapy regimens that pair cisplatin or carboplatin with etoposide, vinorelbine, mitomycin, vindesine, irinotecan, paclitaxel, docetaxel, or pemetrexed have each been studied; unfortunately, few head-to-head trials to compare these agents have been conducted. In a Japanese phase III study, patients were randomly assigned to receive either mitomycin, vindesine, and cisplatin, irinotecan and carboplatin, or carboplatin and paclitaxel, but no significant difference in OS was observed. 16 In the United States, the most common regimens used are cisplatin and etoposide (EP) and dose-reduced weekly carboplatin and paclitaxel (CP) during radiation followed by two cycles of the same agents at systemic doses. Although phase III studies to compare these regimens do not currently exist, a retrospective analysis of Veterans Health Administration data compared the outcomes of 499 patients treated with EP and 1,343 treated with CP. 17 No difference in OS was noted between the two regimens, but EP was associated with increase toxicities and more hospitalizations. This study has several limitations associated with the inherent biases of retrospective studies; however, in the absence of a randomized controlled trial, it is the best data available and suggests that any difference in survival outcomes between the two regimens is likely small. 17 Pemetrexed is a newer agent that has been widely adopted to treat nonsquamous cancers in the metastatic setting. 18 In the PROCLAIM study, patients with stage III nonsquamous histologies were randomly assigned to EP or to cisplatin with pemetrexed, but, after 598 patients were enrolled, the study was stopped early because of futility, and no differences were found between the two arms in terms of OS (26.8 v 25 months; HR, 0.98; 95% CI, 0.79 to 1.20; P 5 .83), median PFS (11.4 v 9.8 months; HR, 0.86; 95% CI, 0.71 to 1.04; P 5 .13), or objective response rate (35.9% v 33%; P 5 0.45). The only clear toxicity difference was a higher incidence of neutropenia in patients treated with EP (54.8% v 44.5%; P # .05). Other regimens recommended by the NCCN guidelines are cisplatin plus vinblastine and carboplatin plus pemetrexed. 5 In the absence of a clear preferred regimen, clinicians and patients need to make a decision about which regimen to prescribe after the following are considered: histology (pemetrexed is only useful for patients with nonsquamous histology), potential toxicities (eg, kidney injury for cisplatin, neuropathy for paclitaxel), length of treatment (CP and pemetrexed-containing regimens have always been studied with consolidation cycles, whereas the role of consolidation for EP and vinblastine-containing regimens is controversial), and cost (pemetrexed is significantly more expensive).
WHAT IS THE ROLE OF CONSOLIDATION CHEMOTHERAPY AFTER DEFINITIVE CHEMOTHERAPY AND RADIATION?
The overall outcome of patients treated with definitive chemoradiation is poor, and less than 20% of patients have longterm survival in contemporary trials. 19 In the adjuvant setting, four cycles of a platinum doublet are given in the majority of the trials, 20 which is similar to the four to six cycles of chemotherapy given in the metastatic setting, where no benefit in OS is seen when the duration of the initial treatment is lengthened. 21 Because most patients will experience recurrence and metastatic disease, an extended duration of chemotherapy beyond what is given during chemoradiation in patients with stage III disease, a practice also known as consolidation chemotherapy, has made theoretical sense. However, the evidence for this is lacking. The Hoosier Oncology Group study randomly assigned patients treated with EP to two cycles of docetaxel or to best supportive care after concurrent chemoradiation. There was no difference in OS (21.2 v 23.2 months; P 5 .88), and patients treated with consolidation had higher incidences of grade 3 or 4 toxicities. 22 Similarly, a phase III study conducted in Korea, China, and Taiwan randomly assigned 437 patients to chemoradiation and weekly cisplatin and docetaxel followed by three cycles of the same agents (35 mg/m 2 each on days 1 and 8, every 3 weeks) or to best supportive care. 23 No differences in the primary end points of PFS or OS were seen between the arms. Last, a pooled analysis of 34 phase II and seven phase III trials to evaluate the role of consolidation reported no improvement in OS with either consolidation approach (adjusted HR, 0.94; 95% CI, 0.81 to 1.09; P 5 .40). 24 For patients treated with CP, the doses of both agents used during chemoradiation are not effective to treat systemic disease; therefore, two consolidation cycles with higher doses are currently recommended. For other regimens, the role of consolidation is controversial; although consolidation is commonly done, 19 there is no scientific evidence that it provides any additional benefit. Therefore, we do not recommend it.
WHAT IS THE OPTIMAL RADIATION DOSE?
With the goal of improving local control rates, several earlyphase studies demonstrated that escalation of the radiation dose up to 74 Gy with chemoradiation was safe and tolerable. Radiation Therapy Oncology Group study RTOG 0617 was a phase III study in which patients were randomly assigned to receive standard treatment with radiation to 60 Gy, using CP as the chemotherapy backbone, or to 74 Gy with the same chemotherapy as the experimental arm. The median OS was 28.7 months for patients who received standard-dose radiotherapy and was 20.3 months for those included in the high-dose radiotherapy arm (HR, 1.38; 95% CI, 1.09 to 1.76; P 5 .004). The reason behind the failure of the experimental arm is a matter of debate. Potential explanations include a higher incidence of treatment-related deaths in the high-dose arm potentially related to heart radiotoxicity and the finding that concurrent chemotherapy was more difficult to complete in the high-dose group. Currently, the 60 to 63 Gy in 1.8-to 2.0-Gy fractions established by the RTOG 7301 study more than 30 years ago remains the standard, and treatment with a higher radiation dose should only be done in the context of a clinical trial.
IS THERE A ROLE FOR SURGERY IN PATIENTS WITH LOCAL RECURRENCE AFTER DEFINITIVE CHEMORADIATION?
Local relapses after definitive chemoradiation are common, and they occur in 30% to 45% of patients. 19, 25 When feasible, and in the absence of systemic disease, patients can be treated with local-modality therapy. Although technically more difficult and with potentially higher morbidity, salvage lung resection can be safely performed, as evidenced by multiple, mostly single-institutional case series, which include our own, that show that both lobectomies and pneumonectomies are feasible, have acceptable toxicities, and can be associated with longterm survival when the patients are chosen appropriately. [26] [27] [28] We recommend that, just as in the initial presentation, treatment for patients with recurrent disease without evidence of distant metastatic sites be discussed in a multidisciplinary conference.
WHAT ABOUT TARGETED THERAPY?
Adding targeted therapy to unselected patients with stage III lung cancer has not been associated with improved outcomes. In a phaseIIIstudyofunselectedpatientswithstageIIIdiseasewhohad received definitive chemoradiation, 243 patients were randomly assigned to receive gefitinib or placebo. Median survival times were longer for the placebo group (35 v 23 months; P 5 .013). 29 Similarly, cetuximab failed to improve outcomes when added to a regimen of CP during radiation, and median OS in patients who received cetuximab was 25 months compared with 24 months in those who did not (HR, 1.07; 95% CI, 0.84 to 1.35; P 5 .29). 25 It is now established that patients who have a mutation in the activating portion of the EGFR gene are the ones who experience the most benefit from targeting the epidermal growth factor receptor (EGFR). 30, 31 The NRG Oncology and Alliance cooperative groups are currently performing a randomized, phase II study of individualized therapy for stage III NSCLC (RTOG 1306/Alliance 31101, NCT01822496), in which patients will receive induction therapy with erlotinib for 12 weeks followed by definitive chemoradiation with EP or CP. Another 7% of patients with NSCLC have a translocation, which leads to a fusion gene between echinoderm microtubuleassociated protein-like 4 and anaplastic lymphoma kinase. This acts as a driver mutation; consequently, inhibition of this fusion gene with agents such as crizotinib has led to dramatic responses in this patient population, which resulted in improved PFS and quality of life. 32 The RTOG 1306 study also has an arm with crizotinib for 12 weeks as induction treatment.
DOES IMMUNOTHERAPY HAVE A ROLE IN THE TREATMENT OF STAGE III DISEASE?
The use of immunotherapy to target the immune checkpoint axis of programmed death 1 (PD-1)/programmed death ligand 1 (PD-L1) has recently changed the paradigm of how we treat patients with metastatic NSCLC. Nivolumab and pembrolizumab, both antibodies directed against PD-1, have been recently approved for the treatment of NSCLC. Nivolumab in particular has recently been shown to improve OS in patients with metastatic disease after progression occurred during treatment with a platinum doublet. 33, 34 MEDI4736 is a PD-L1 inhibitor that is currently being studied in the PACIFIC trial, a study in which patients who have completed definitive chemoradiation are randomly assigned to this agent or to placebo (NCT02125461). The RTOG and NRG are currently developing a similar trial that uses nivolumab as consolidation after chemoradiation. In a separate strategy, Alliance is developing a trial that will investigate the neoadjuvant administration of a still-undefined PD-1/PD-L1 inhibitor.
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IS THERE BENEFIT OF INTENSE RADIOLOGIC FOLLOW-UP AFTER CURATIVE THERAPY FOR STAGE III DISEASE?
It is estimated that approximately half of the real health care expenditure growth can be attributed to medical technology. 36 Radiology represents a significant component of that. There are two main reasons to provide radiologic follow-up of asymptomatic patients after curative chemoradiotherapy. The first is to detect a new primary lesion to which curative therapy can be delivered. There is no evidence that this goal can be achieved with yearly or more frequent CT scans, because patients with a prior diagnosis of lung cancer were excluded from the National Lung Screening Trial. 37 However, it is true that the risk of a second primary is high and that many institutions, including ours, and NCCN guidelines do recommend yearly chest CT scans with the goal of early diagnosis of a second primary. The second reason for the radiologic follow-up is to make an early diagnosis of progression. This could, theoretically, prevent the development of cancer symptoms with early initiation of palliative therapy or even allow for curative therapy in selected cases. Although surgical resection after full-dose chemoradiotherapy is feasible, 26 38 As expected, patients enrolled in clinical trials had more body (2.9 v 2 per year; P 5 .0016) and brain (1.1 v 0.4; P , .001) scans. Although 44 patients experienced recurrence, 64% of those patients sought medical attention because of symptoms that developed between scheduled visits or procedures. There was no difference in survival between the two groups. Although a high standardized uptake value on a posttherapy PET scan can predict a poor outcome in patients treated with chemoradiotherapy, 39 the clinical utility of this information is limited. A recent study used Surveillance, Epidemiology, and End Results and Medicare combined data to evaluate the survival of patients with lung and esophageal cancer on the basis of the number of PET scans done to detect recurrences. 40 Comparison between groups with the highest and lowest utilization of PET scans showed no difference in survival.
In conclusion, stage III NSCLC occurs in a heterogenous group of patients, and many questions about how to best treat these patients remain unanswered. As new therapies are beneficial in the metastatic setting, and as we begin to use them in earlier-stage disease, many of these questions will remain unanswered and many new ones will surface, which underscores the need to prioritize clinical trials in this patient population. 
